Oncogene activation in pituitary tumors

Brain Pathology

Volumn 11, Issue 3, 2001, Pages 328-341

  Yu, Run ^a   Melmed, Shlomo ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; CYCLIN D1; FIBROBLAST GROWTH FACTOR; GROWTH HORMONE; PROTEIN P53; STIMULATORY GUANINE NUCLEOTIDE BINDING PROTEIN;

ANEUPLOIDY; APOPTOSIS; CARCINOGENESIS; CELL PROLIFERATION; CELLULAR DISTRIBUTION; CONFERENCE PAPER; GENE ACTIVATION; GENE AMPLIFICATION; GENE MUTATION; GENE OVEREXPRESSION; GROWTH HORMONE RELEASE; HUMAN; HYPOPHYSIS ADENOMA; HYPOPHYSIS TUMOR; NONHUMAN; ONCOGENE; ONCOGENE C MYC; POSITIVE FEEDBACK; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; TRANSACTIVATION; TUMOR VASCULARIZATION;

EID: 0034981804     PISSN: 10156305     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1750-3639.2001.tb00403.x     Document Type: Conference Paper

References (91)

1. Clinically nonfunctioning pituitary tumors are monoclonal in origin
2. The cytogenesis and pathogenesis of pituitary adenomas
3. The cyclic adenosine 3′,5′-monophosphate-responsive factor CREB is constitutively activated in human somatotroph adenomas
4. Molecular genetic studies of sporadic pituitary tumors
5. Identification of the human pituitary tumor transforming gene (hPTTG) family: Molecular structure, expression, and chromosomal localization
6. A novel binding factor facilitates nuclear translocation and transcriptional activation function of the pituitary tumor-transforming gene product
7. Human pituitary tumors have multiclonal origins
8. Comparative genomic hybridization analysis of nonfunctioning pituitary tumors
9. Wild-type p53 mediates apoptosis by E1A, which is inhibited by E1B
10. hpttg, a human homologue of rat pttg, is overexpressed in hematopoietic neoplasms. Evidence for a transcriptional activation function of hPTTG
11. Molecular pathogenesis of pituitary tumors
12. Cut2 proteolysis required for sister-chromatid separation in fission yeast
13. Cytogenetic alterations in pituitary adenomas detected by comparative genomic hybridization
14. Rb function in cell-cycle regulation and apoptosis
15. Early involvement of estrogen-induced pituitary tumor transforming gene and fibroblast growth factor expression in prolactinoma pathogenesis
16. Pituitary tumor transforming gene: A novel marker in colorectal tumors
17. New pituitary oncogenes
18. Mediation of c-myc induced apoptosis by p53
19. Clonal origin of pituitary adenomas
20. Molecular screening of pituitary adenomas for gene mutations and rearrangements
21. Analysis of cyclin D1 (CCND1) allelic imbalance and overexpression in sporadic human pituitary tumors
22. Analysis of the Gs alpha gene in growth hormone-secreting pituitary adenomas by the polymerase chain reaction-direct sequencing method using paraffin-embedded tissues
23. Detection of chromosomal imbalances in growth hormone-secreting pituitary tumors by comparative genomic hybridization
24. Cyclins and cancer. II: Cyclin D and CDK inhibitors come of age
25. Effects of cyclin D1 overexpression on G1 progression-related events
26. Human pituitary tumor-transforming gene induces angiogenesis
27. DNA aneuploidy in adenomas of endocrine organs
28. Vasculature in nontumorous hypophyses, pituitary adenomas and carcinomas: A quantitative morphologic study
29. Molecular cloning, genomic organization, and identification of the promoter for the human pituitary tumor transforming gene (PTTG)
30. Ras mutations in human pituitary tumors
31. A lipid-anchored Grb2-binding protein that links FGF-receptor activation to the Ras/MAPK signaling pathway
32. GTPase inhibiting mutations activate the alpha chain of Gs and stimulate adenylyl cyclase in human pituitary tumours
33. Clinical characteristics of acromegalic patients whose pituitary tumors contain mutant Gs protein
34. Activation of the MAP kinase pathway by FGF-1 correlates with cell proliferation induction while activation of the Src pathway correlates with migration
35. p53, the cellular gatekeeper for growth and division
36. Aneuploidy vs. gene mutation hypothesis of cancer: Recent study claims mutation but is found to support aneuploidy
37. Tumour ploidy in DNA histograms of pituitary adenomas
38. Two G protein oncogenes in human endocrine tumors
39. Multiple endocrine neoplasia type 1: Clinical and genetic topics
40. Multiple endocrine neoplasia type 1: Clinical and genetic features of the hereditary endocrine neoplasias
41. Pituitary tumor transforming gene (pttg), basic fibroblast growth factor (fgf-2) and vascular endothelial growth factor (vegf) expression in sporadic pituitary adenomas
42. Pituitary neoplasia
43. Pituitary function and neoplasia
44. Pathogenesis of pituitary tumors
45. Multiple genetic aberrations including evidence of chromosome 11q13 rearrangement detected in pituitary adenomas by comparative genomic hybridization
46. Cyclin D and oncogenesis
47. Role of the Rb/E2F pathway in cell growth control
48. Transfection of human mutated K-ras in mouse NIH-3T3 cells is associated with increased cloning efficiency and DNA aneuploidization
49. Ordering S phase and M phase in the cell cycle
50. H-ras mutations in human pituitary carcinoma metastases
51. Frequent loss of heterozygosity at the retinoblastoma susceptibility gene (RB) locus in aggressive pituitary tumors: Evidence for a chromosome 13 tumor suppressor gene other than RB
52. Oncogenes and tumor suppressor genes in pituitary tumorigenesis
53. Isolation and characterization of a pituitary tumor transforming gene (PTTG)
54. Genomic organization and identification of an enhancer element containing binding sites for multiple proteins in rat pituitary tumor-transforming gene
55. Activation of mitogen-activated protein kinase cascade regulates pituitary tumor-transforming gene transactivation function
56. Identification of c-Myc as a down-stream target for pituitary tumor-transforming gene
57. Molecular characterization of the men1 tumor suppressor gene in sporadic pituitary tumors
58. An intronless homolog of human proto-oncogene hPTTG is expressed in pituitary tumors: Evidence for hPTTG family
59. Cell cycle regulated expression and phosphorylation of hpttg protooncogene product
60. Ectopic expression of cyclin D1 but not cyclin E induces anchorage-independent cell cycle progression
61. hpttg is over-expressed in pituitary adenomas and other primary epithelial neoplasias
62. c-Myc induces apoptosis in epithelial cells by both p53-dependent and p53-independent mechanisms
63. Chromosomes in solid tumors and beyond
64. Ultrastructural changes in the capillary bed of human pituitary tumours
65. D-type cyclins
66. Genetic basis of endocrine disease: Pituitary tumor pathogenesis
67. Molecular pathogenesis of pituitary adenomas: A review
68. Adenovirus E1A proteins induce apoptosis by both p53-dependent and p53-independent mechanisms
69. The many roles of c-Myc in apoptosis
70. Activating mutations of the Gs alpha-gene in nonfunctioning pituitary tumors
71. C-myc-induced apoptosis in polycystic kidney disease is Bcl-2 and p53 independent
72. Angiogenesis in pituitary adenomas and the normal pituitary gland
73. Abnormalities of the human growth hormone gene and protooncogenes in some human pituitary adenomas
74. Characterization of the murine pituitary tumor transforming gene (PTTG) and its promoter
75. Pituitary tumor transforming gene (PTTG) transforming and transactivation activity
76. Gs alpha and Gi2 alpha mutations in clinically non-functioning pituitary tumours
77. G-protein mutations in human pituitary adrenocorticotrophic hormone-secreting adenomas
78. c-myc, c-fos, and c-myb gene expression in human pituitary adenomas
79. C-myc overexpression and p53 loss cooperate to promote genomic instability
80. Rare mutations of the Gs alpha subunit gene in human endocrine tumors. Mutation detection by polymerase chain reaction-primer-introduced restriction analysis
81. Pituitary tumor transforming gene (PTTG) regulates placental JEG-3 cell division and survival: Evidence from live cell imaging
82. Pituitary tumor transforming gene causes aneuploidy and p53-dependent and p53-independent apoptosis
83. The chromosomal basis of human neoplasia
84. Increased mitogenic responsiveness of Swiss 3T3 cells expressing constitutively active Gs alpha
85. Structure, expression, and function of human pituitary tumor-transforming gene (PTTG)
86. Pituitary tumor transforming gene (PTTG) expression in pituitary adenomas
87. Mutations of the MEN1 tumor suppressor gene in pituitary tumors
88. Identification of a vertebrate sister-chromatid separation inhibitor involved in transformation and tumorigenesis
89. Securin degradation is mediated by fzy and fzr, and is required for complete chromatid separation but not for cytokinesis